Delivery Order SPE2DB20D3103-SPE2DB25FQ3T6
- Not listed
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a delivery order valued at $9,380.82 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $11,417.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication primarily used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $2,528.46 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive delivery order utilizes firm fixed price terms and will be performed at the contractor's Conshohocken, Pennsylvania location. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and...
- The Defense Logistics Agency awarded a $24,210.12 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on September 3, 2025, with completion targeted for September 4, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order valued at $25,223.18 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded a delivery order valued at $25,566.25 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $27,925.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 11, 2025, with completion expected by August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ3T6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $19,592.42 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on September 18, 2025, with completion scheduled for September 19, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, representing a specialized pharmaceutical product critical to military and federal healthcare systems. This delivery order represents a single transaction under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a prime vendor supplying comprehensive medical commodities across multiple therapeutic domains to support defense health operations globally. The company's extensive federal contract portfolio demonstrates its capability to meet specialized pharmaceutical procurement requirements through open competition and deliver critical medications to support military healthcare programs and the Defense Health Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.6k | 9/18/25 |